Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Sunshine Biopharma Inc.
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
May 28, 2026
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin
May 21, 2026
Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering
May 19, 2026
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
May 18, 2026
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
April 6, 2026